Zinbryta (daclizumab) was removed from the market and is no longer available. Please see our Society News for additional information.
Zinbryta™ is a laboratory-created monoclonal antibody. It is designed to inhibit certain inflammatory functions of T cells and increase important immune cells that help regulate the immune system.
Zinbryta is approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with relapsing forms of MS. It should be reserved for people who have had an inadequate response to two or more disease-modifying medications.
to read the Zinbryta Prescribing Information for healthcare professionals.
to read the Zinbryta Medication Guide for patients.
Financial Assistance ProgramWITHDRAWN FROM MARKET -- MARCH 2, 2018
Please see our Society News for additional information.